C
Cairn Therapeutics
Aiding in the fight against cancer through the development of a prodrug, CT 262, which selectively targets and inhibits tumor growth while sparing healthy cells
About Cairn Therapeutics
Cairn Therapeutics is focused on developing advanced cancer treatments, specifically through its innovative compound CT 262. This prodrug is selectively activated within cancer cells, targeting DNA to induce programmed cell death while sparing healthy cells. The company operates in the oncology market, serving patients and healthcare providers seeking effective cancer therapies. Cairn Therapeutics' business model revolves around the research, development, and eventual commercialization of its proprietary compounds. Revenue is generated through partnerships, licensing agreements, and future sales of its therapeutic products. CT 262 has shown promising results in preclinical studies, demonstrating high efficacy and a broad therapeutic window. The company aims to provide a significant advancement in cancer treatment, offering a solution that inhibits tumor growth in a dose-dependent manner and continues its effects even after the last dose.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2016
- Headquarters
- Wilmington, United States
- Employees
- 4
- Open positions
- None listed
- Dealroom signal
- 26.3/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Oct 2024 | $15M | $60M | Undisclosed | ↗ |
| EARLY VC✓Equity / VC | Oct 2024 | $4M | $16M | Undisclosed | ↗ |
Growth signals
Latest recorded traffic for Cairn Therapeutics is 980 monthly website visits, up 2.1% over the last three months. Cairn Therapeutics's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Cairn Therapeutics in the Wilmington ecosystem
The Cairn Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Other known investors1 additional known investor
Scripps Translational Science Institute
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Cairn Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Cairn Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










